Trombociti i koronarna bolest
|
|
- Melvin Davidson
- 6 years ago
- Views:
Transcription
1 Trombociti i koronarna bolest Prof. dr. sc. Mislav Vrsalović FESC, FSVM Trombociti - interdisciplinarni pristup Zagreb, 11. studenoga 2017.
2 Atherothrombosis* is the Leading Cause of Death Worldwide 1 Pulmonary Disease 6.3 Injuries AIDS Cancer 12.6 Infectious Disease 19.3 Atherothrombosis* Causes of Mortality (%) * Atherothrombosis defined as ischemic heart disease and cerebrovascular disease. 1 The World Health Report Geneva. WHO
3 Years Atherothrombosis Significantly Shortens Life Atherothrombosis reduces life expectancy by around 8-12 years in patients aged over 60 years 1 20 Average Remaining Life Expectancy at Age 60 (Men) years -9.2 years -12 years Healthy History of Cardiovascular Disease History of AMI History of Stroke Analysis of data from the Framingham Heart Study. Peeters A, et al. Eur Heart J. 2002;23:
4 Clinical Manifestations of Atherothrombosis Cerebral Ischemic stroke Transient ischemic attack Cardiac Myocardial infarction Angina pectoris (stable, unstable) Peripheral Arterial Disease Critical limb ischemia, claudication
5 Common Underlying Atherothrombotic Disease Process Atherothrombotic Stroke Unstable Angina MI PAD Plaque Rupture Platelet Adhesion, Activation, and Aggregation Thrombus Formation Atherothrombotic Events (MI, Stroke, or CV Death) MI, myocardial infarction; PAD, peripheral arterial disease; CV, cardiovascular. Ness J, et al. J Am Geriatr Soc. 1999;47: Schafer AI. Am J Med. 1996;101:
6 Risk of a Second Atherothrombotic Event Increased Risk vs General Population (%) Original Event MI Stroke MI Stroke PAD 5-7 times greater risk (includes death)* 2-3 times greater risk (includes angina and sudden death)* 4 times greater risk* 3-4 times greater risk (includes TIA) 9 times greater risk 2-3 times greater risk (includes TIA) * Death documented within 1 hour of an event attributed to CHD. Note:This chart is based on epidemiologic data and is not intended to provide a direct basis for comparison of risks between event categories. MI, myocardial infarction; TIA, transient aschemic attack, PAD, peripheral artery disease. Adult Treatment Panel II. Circulation. 1994;89: Kannel, WB. J Cardiovasc Risk. 1994;1: Wilterdink, JI, et al. Arch Neurol. 1992;49: Crique, MH, et al. N Engl J Med. 1992;326:
7 Atherothrombosis: A Generalized and Progressive Process Thrombosis Atherosclerosis Unstable angina MI Ischemic stroke/tia Critical leg ischemia Intermitent claudication CV death ACS Stable angina/ Intermittent claudication Adapted from Libby P. Circulation. 2001;104:
8 Atherothrombosis: Thrombus Superimposed on Atherosclerotic Plaque Adapted from Falk E, et al. Circulation. 1995;92:
9 Characteristics of Unstable and Stable Plaque Unstable Stable Few SMCs Thin fibrous cap Inflammatory cells More SMCs Thick fibrous cap Lack of inflammatory cells Eroded endothelium Activated macrophages Intact endothelium Foam cells Libby P. Circulation. 1995;91:
10 Plaque Rupture Andrew Farb, MD by permission.
11 Risk Factors for Plaque Rupture Local Factors Atheromatous Core (size/consistency) Cap Fatigue Cap Thickness/ Consistency Cap Inflammation Smoking Diabetes Mellitus Homocysteine Cholesterol Systemic Factors Fibrinogen Impaired Fibrinolysis Fuster V, et al. N Engl J Med. 1992;326: Falk E, et al. Circulation. 1995:92: Plaque Rupture
12
13 Akutni koronarni sindrom
14 Smrtnost bolesnika s AKS je i dalje visoka Smrtnost bolesnika s AKS-om kod kojih je napravljena PCI u prvoj godini nakon dijagnoze 1 AKS akutni koronarni sindrom; NAP nestabilna angina pektoris NSTEMI infarkt miokarda bez ST elevacije; STEMI infarkt miokarda sa ST elevacijom - Svakih 12 sati u Hrvatskoj umru najmanje 2 osobe zbog AKS-a. 2
15 ACS: Tip of the Atherothrombotic Iceberg Acute Plaque Rupture ACS (UA/NSTEMI/STEMI) Clinical Subclinical Presence of Multiple Coronary Plaques Persistent Hyperreactive Platelets Vascular Inflammation ACS, acute coronary syndrome; UA, unstable angina; NSTEMI, non-st-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction. Adapted from Goldstein JA. J Am Coll Cardiol. 2002;39:
16 Hemostatic Plug Formation PRIMARY AGGREGATION Platelet Aggregation Clotting Hemostatic Clot SECONDARY COAGULATION Thrombin Fibrin 0 min 10 min 5 min Adapted from Ferguson JJ, et al. Antiplatelet Therapy in Clinical Practice. 2000:15-35.
17
18 Platelets Role in Thrombosis Platelet 1. Platelet Adhesion GP Ib 2. Platelet Activation Plaque rupture ASA, Clopidogrel/Ticlopidine Activated Platelet GP IIb/IIIa TxA2 GP IIb/IIIa Inhibitors Fibrinogen ASA, acetylsalicyclic acid. Cannon and Braunwald, Heart Disease
19 Activated Platelet Clopidogrel Ticlopidine To neighboring platelet IV Gp IIb/IIIa Inhibitors Gp IIb/IIIa fibrinogen receptor Activation COX Aspirin Thrombin Serotonin Epinephrine Collagen Adhesive proteins thrombospondin fibrinogen p-selectin vwf Coagulation factors factor V factor XI PAI-1 Degranulation Inflammatory factors platelet factor 4 CD 154 (CD 40 ligand) PDGF Platelet agonists ADP ATP serotonin calcium magnesium TXA, thromboxane; PDGF, platelet-derived growth factor.
20 Patients (%) ACS, acute coronary syndrome. * Relative risk compared to group with negative aggregation. Adapted from Trip MD, et al. N Engl J Med. 1990;322: Platelet Hyperreactivity Following ACS Predicts 5-Year Outcomes 50 Death Cardiac Events 40 *RR= (CI ) *RR=1.6 (CI ) *RR=3.1 (CI ) 46.2 *RR=5.4 (CI ) Negative (n=94) Intermediate (n=29) Platelet Aggregability Status Positive (n=26)
21 erapija AKS Antiishemijski lijekovi Antikoagulansi -UFH ili LMWH -fondaparinux -bivalirudin Antiagregacijska th. -ASK -klopidogrel -Gp IIb/IIIa inhibitori Revaskularizacija
22
23 Antitrombocitna terapija: klopidogrel preko 10 godina životnog iskustva na širokom spektru bolesnika 10 kliničkih ispitivanja uključijući preko bolesnika Učinkovitost i sigurnost klopidogrela dokazana je na preko 130 milijuna bolesnika u svijetu Okosnica antitrombocitne terapije Prasugrel i tikagrelor novi antitrombotici Approved 2011
24
25 Antiplatelet Mechanism of Action Aspirin blocks cyclooxygenase, the enzyme that mediates the first step in the biosynthesis of prostaglandins and thromboxanes from arachidonic acid, preventing platelet aggregation The P2Y 12 (ADP) receptor blockers (clopidogrel, etc.) block the binding of adenosine diphosphate (ADP) to a platelet receptor P2Y 12, thereby inhibiting activation of the glycoprotein (GP) IIb/IIIa complex and platelet aggregation Anti-GP IIb/IIIa antibodies and receptor antagonists inhibit the final common pathway of platelet aggregation (the crossbridging of platelets by fibrinogen binding to the GP IIb/IIIa receptor)
26 Aspirin Platelets do not synthesize new enzymes functional defect induced by aspirin persists for the life of the platelet (nonreversible) In ACS, including Unstable Angina and NSTEMI: reduction in the combined endpoints of subsequent nonfatal MI, nonfatal stroke, and vascular death Give first dose in ACS of mg, crushed or chewed, as soon as possible in ACS ASA has rapid and immediate antithrombotic effect Discharge patient on ASA mg daily and to be continued indefinitely for secondary prevention Side effects: GI intolerance, worsening of preexistent bleeding Primary Prevention 1. Benefit of ASA must be weighed against risk of bleeding 1. Risk of bleeding likely to outweigh benefits in patients w/ Framingham 10 year risk scores < 10% 2. Consider in patients with DMII and those with CKD as well as patients w/ Framingham risk scores > 10%
27 ADP receptor antagonists (P2Y 12 receptor blockers) Ticlopidine: rarely used anymore due to risk of thrombocytopenia, neutropenia, GI upset and TTP-HUS Clopidogrel: DAPT with Clopidogrel and ASA was superior compared to ASA alone in patients w/ NSTEMI 3 limitations to the use of clopidogrel Delayed onset of action Large individual variability in platelet response due to mutation in CYP2C19 allele decreased platelet inhibition and increase in ischemic events Inhibitory effect on platelets is Irreversible Prasugrel: more rapid onset of action and achieves higher degrees of platelet inhibition than clopidogrel Compared with Clopidogrel, 19% reduction in cardiovascular death/mi/stroke when given at time of planned PCI, however bleeding risk greatly increased (including life-threatening bleed) Contraindicated in patients w/ history of stroke, age > 75 years, or weight < 60 kg
28 Ticagrelor Binds reversibly to the P2Y 12 platelet receptor More rapid onset of action than clopidogrel More intense platelet inhibition than clopidogrel Data reveals better *efficacy* than clopidogrel with reduction in cardiovascular death, MI, stroke in patients with ACS
29 Klopidogrel: preko 10 godina kliničkog iskustva ~130,000 bolesnika liječenih klopidogrelom u 10 kliničkih ispitivanja ~130 milijuna bolesnika liječenih u svakodnevnoj kliničkoj praksi Publicirana ispitivanja Indikacija u STEMI Indikacija u AF ACTIVE CURRENT CURRENT Indikacija u UA/NSTEMI COMMIT CCS2 CHARISMA CHARISMA COMMIT CCS2 COMMIT CCS2 CLARITY CLARITY CLARITY CLARITY CHARISMA COMMIT CCS2 CLARITY Indikacija nakon IM, CVI ili dokazane PAB CARESS CARESS CARESS CARESS CARESS MATCH MATCH MATCH MATCH MATCH MATCH CARESS MATCH CREDO CREDO CREDO CREDO CREDO CREDO CREDO CREDO CURE (PCI-CURE) CURE (PCI-CURE) CURE (PCI-CURE) CURE (PCI-CURE) CURE (PCI-CURE) CURE (PCI-CURE) CURE (PCI-CURE) CURE (PCI-CURE) CURE (PCI-CURE) CLASSICS CLASSICS CLASSICS CLASSICS CLASSICS CLASSICS CLASSICS CLASSICS CLASSICS CLASSICS CAPRIE CAPRIE CAPRIE CAPRIE CAPRIE CAPRIE CAPRIE CAPRIE CAPRIE CAPRIE CAPRIE Data on file 2. IMS data MAT 12/10 Godina publikacije
30 Klopidogrel: manje združenih događaja KV smrti, IM ili CVI nakon PCI Meta analiza PCI-CURE, PCI-CLARITY i CREDO: konzistentan povoljan učinak liječenja klopidogrelom na KV smrti, IM ili moždani udar nakon PCI: 28% smanjenje događaja u bolesnika koji nisu primali GP IIb/IIIa inhibitor u vrijeme PCIa i 31% smanjenje događaja u bolesnika liječenih GP IIb/IIIa inhibitorom Sabatine MS et al. Am Heart J 2008;155: KV-kardiovaskularni, IM-infarkt miokarda, MU-moždani udar, PCI-perkutana koronarna intervencija
31 Klopidogrel: bez signifikantnog povećanja broja TIMI velikih ili manjih krvarenja nakon PCI Meta-analiza PCI-CURE, PCI-CLARITY i CREDO: Primjena klopidogrela nije bila povezana sa signifikantnim porastom kompozitnog ishoda TIMI major i minor krvarenja, bez obzira na primjenu GP IIb/IIIa inhibitora Sabatine MS et al. Am Heart J 2008;155:
32 Zašto je krvarenje važno? Smrtnost i krvarenje u bolnici nakon PCI krvarenja u bolnici usko koreliraju sa smrtnošću nakon PCI Peterson ED ACC 2007 Mehta SR ACC 2007 PCI-perkutana koronarna intervencija
33 Događaji (%) COMMIT: klopidogrel smanjuje kombinirani ishod smrti, IM ili CVI za 9% u STEMI 10 8 Placebo (10.1%) klopidogrel (9.3%) RRR=9% P= Hour to entry Clopidogrel Placebo Odds ratio & 95% CI (22,958) (22,891) Clopid. better Placebo better (9.3%) 672 (9.7%) 904 (10.9%) 735 (10.7%) ALL 666 (8.8%) 2125 (9.3%) 666 (8.7%) 2311 (10.1%) 9% SE 3 (2P = 0.002) Chen ZM. Lancet 2005;366: Dani od randomizacije
34 Kumulativni rizik CURRENT OASIS 7: Klopidogrel dvostruka vs standardna doza: primarni ishod - PCI bolesnici CV smrt, IM ili moždani udar Klopidogrel standardna doza Klopidogrel dvostruka doza HR % CI P= % RRR Dani Mehta SR, et al. Lancet 2010;376:
35 Kumulativni rizik CURRENT OASIS 7: Klopidogrel dvostruka vs standardna doza Stent tromboza (potvrđena angiografski) Klopidogrel standardna doza Klopidogrel dvostruka doza HR % CI P= % RRR Mehta SR, et al. Lancet 2010;376: Dani
36 Što je s novim antitrombocitnim lijekovima? učinkovitost: početak djelovanja sigurnost: krvarenja
37 Prasugrel vs klopidogrel: PCI bolesnici smanjenje događaja uz veći rizik od krvarenja TRITON TIMI: Wiviott, N Engl J Med 2007;357:
38 Prasugrel vs klopidogrel: TRILOGY ACS bez razlike u događajima nema razlike u kompozitnim događajima (KV smrt, IM, CVI) između prasugrela i klopidogrela u prvoj godini Medikamentozno liječeni visokorizični bolesnici sa UA/NSTEMI (bez revaskularizacije)
39 Tikagrelor vs klopidogrel: smanjenje događaja uz veći rizik od ne-cabg krvarenja i fatalnih intrakranijalnih krvarenja PLATO: Walletin, N Engl J Med 2009;361:1-13
40 Ograničenja prilikom upotrebe novih antitrombotičkih lijekova PRASUGREL u bolesnika s visokim rizikom od krvarenja, osobito: - bolesnici stariji od 75 godina - bolesnici lakši od 60 kg kontraindikacija - CVI/TIA u anamnezi TIKAGRELOR kontraindikacija intrakranijalno krvarenje u anamnezi posebna upozorenja povećani rizik od krvarenja - Povećani rizik od ne-cabg krvarenja (AKS bolesnici na tikagreloru i ASK) češća pojava dispneja (oprez kod bolesnika s astmom i KOPB-om) suradljivost - 2 tbl. na dan (doza održavanja) MU-moždani udar, TIA-tranzitorna ishemična ataka; ASK-acetilsalicilna kiselina
41 ESC smjernice za liječenje NSTEMI - P2Y12 inhibitori a50% inhibicija agregacije trombocita Grupa I, razina B The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without ST-segment elevation of the European Society 42 of Cardiology (ESC). ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent STsegment elevation. European Heart Journal. Published online 26 August 2011
42 TIKAGRELOR: Prvi i jedini odobreni CPTP TIKAGRELOR pripada novoj kemijskoj skupini; ciklopentil-triazolo-pirimidina (CPTP) je aktivna supstanca, ne zahtjeva prethodnu pretvorbu u aktivan oblik je selektivni antagonist receptora adenozin difosfata (ADP) Vezuje se direktno i reverzibilno na P2Y 12 receptore i na taj način sprječava ADP-om posredovanu aktivaciju i agregaciju trombocita Tienopiridini (klopidogrel) zahtjevaju prethodnu pretvorbu u aktivan oblik i vezuju se ireverzibilno za P2Y 12 receptor ADP mjesto vezanja BRILIQUE P2Y 12 receptor na trombocitu Husted S, et al. Eur Heart J. 2006;27: Gurbel PA, et al. Expert Opin Drug Metab Toxicol. 2009;5(8): Van Giezen JJ, et al. J Thromb Haemost. 2009;7:
43 TIKAGRELOR: Nije potrebna prethodna aktivacija BRILIQUE: NIJE POTREBNA PRETHODNA AKTIVACIJA LIJEKA Aktivan oblik Intermedijarni metabolit Predlijek Klopidogrel: PREDLIJEK ZAHTJEVA PRETHODNU PRETVORBU U AKTIVAN OBLIK Prilagođeno iz Schomig A. N Engl J Med. 2009;361:
44 Inhibicija agregacije trombocita (IPA) TIKAGRELOR - Brz početak djelovanja * * * * BRILIQUE (n=54) 60 Klopidogrel (n=50) 40 * 20 *P< BRILIQUE vs klopidogrel BRILIQUE Klopidogrel Placebo Placebo (n=12) 0 Udarna doza Vrijeme (sati) BRILIQUE 180-mg udarna doza kod stabilnih CAD pacijenata Klopidogrel 600-mg udarna doza kod stabilnih CAD pacijenata Veza između IPA i kliničke aktivnosti još nije potvrđena Prilagođeno iz Gurbel PA, et al. Circulation. 2009;120:
45 Klinička farmakologija: TIKAGRELOR i klopidogrel TIKAGRELOR Klopidogrel Kemijska klasa CPTP tienopiridini Reverzibilna inhibicija P2Y 12 receptora DA NE PD varijabilnost CYP2C19 genotipa NE DA Doziranje 2 puta dnevno (bid) jednom dnevno (qd) Srednja inhibicija agregacije trombocita nakon 30 min Srednja inhibicija agregacije trombocita nakon 2 sata 41% 8% 89% 38% Gurbel PA, et al. Circulation. 2009;120: Sažetak opisa svojstava lijeka Brilique (BRILIQUE) PLAVIX [Uputa o lijeku, Hrvatska]..
46 TIKAGRELOR ima dvostruki mehanizam djelovanja: antitrombocitni učinak i pojačan adenozinski odgovor Trombocit ENT-1 Eritrocit Adenozin AC camp ADP A 2A P2Y 12 Gs Aktivacija/agregacija trombocita Gi Tikagrelor Inhibicija receptora P2Y 12 1,2 Antitrombocitni učinak Inhibicija ENT-1 transportera 3,4,5 Poboljšan lokalni adenozinski odgovor može rezultirati:* Dodatna inhibicija agregacije/aktivacije trombocita Kardioprotekcija 6 Vazodilatacija 5,7,8 Modulacija upale Dispneja 7 1. van Giezen JJJ, et al. J Thromb Haemost 2009;7: Wallentin L. Eur Heart J 2009;30: Nylander S, et al. J Thromb Haemost 2013;11: Armstrong D, et al. J Cardiovasc Pharmacol Ther; In press. 5. van Giezen JJJ, et al. J Cardiovasc Pharmacol Ther 2012;17: Wang K, et al. Thromb Haemost. 2010;104: Wittfeldt A, et al. J Am Coll Cardiol 2013;61: Alexopoulos D, et al. Circ Cardiovasc Interv 2013;19: Figure adapted from Nylander S, et al. (2013). AC, adenylyl cyclase; ADP, adenosine diphosphate; camp, cyclic adenosine monophosphate; ENT, equilibrative nucleoside transporter. References in slide notes.
47 TIKAGRELOR: Smanjenje kardiovaskularne smrtnosti u bolesnika s AKS-om ARR apsolutno smanjenje rizika; RRR relativno smanjenje rizika; HR omjer rizika NNT potreban broj liječenih osoba da bismo spriječili jedan događaj CI interval pouzdanosti Wallentin L, et al.n Engl J Med. 2009;361:
48 TIKAGRELOR ne pokazuje značajne razlike u cjelokupnom broju teških, smrtonosnih i po život opasnih krvarenja Učestalost krvarenja definirano po PLATO-u i TIMI-ju * * TIMI tromboliza kod infarkta miokarda Wallentin L, et al. N Engl J Med. 2009;361:
49
50
51
52
Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationStephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
More informationOral Antiplatelet Therapy in PCI/ACS. Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine
Oral Antiplatelet Therapy in PCI/ACS Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine Basic Concepts Thrombus Formation Two key elements:
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationP2Y 12 blockade. To load or not to load before the cath lab?
UPDATE ON ANTITHROMBOTICS IN ACUTE CORONARY SYNDROMES P2Y 12 blockade. To load or not to load before the cath lab? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria,
More informationSurveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management
Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management Jeffrey S Berger, MD, MS Assistant Professor of Medicine and Surgery Director of Cardiovascular Thrombosis Disclosures
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium
ACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium 4/14/2011 Cumulative death rates in 3721 ACS patients from UK and Belgium at ± 5 year (GRACE) 25 20 15 19% TOTAL 14%
More informationDisclosures. Research consulting with: Sanofi-Regeneron Pfizer The Medicines Company Astra Zeneca
Antiplatelet Therapy in Coronary Artery Disease -2015 What are the roles for newer therapies? How do you decide what to cover? R. Scott Wright, MD, FACC, FESC, FAHA Professor of Medicine, Mayo Clinic College
More informationNew antiplatelets in NSTEMI. Overview: dual anti-platelet oral therapy
Cairo, Egypt 2010 New antiplatelets in NSTEMI Steen D. Kristensen, FESC Department of Cardiology Aarhus University Hospital Skejby Denmark Overview: dual anti-platelet oral therapy Aspirin Clopidogrel
More informationPrasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center
Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationOral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!
Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death! Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationClopidogrel has been evaluated in clinical trials that included cardiovascular patients
REVIEW ARTICLE Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations Lessons From the CAPRIE and CURE Studies Jack Hirsh, CM, MD, FRCPC, FRACP, FRSC, DSc; Deepak L. Bhatt, MD,
More informationDECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
More informationP 2 Y 12 Receptor Inhibitors
P 2 Y 12 Receptor Inhibitors Clopidogrel, Prasugrel and Ticagrelor Which Drug and for Whom? Cheol Whan Lee, MD Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan Medical
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationOptimal medical therapy in patients with stable CAD
Optimal medical therapy in patients with stable CAD Robert Storey Professor of Cardiology, University of Sheffield and Academic Director and Honorary Consultant Cardiologist, Cardiology and Cardiothoracic
More informationAntiplatelet in diabetics: strong but incomplete umbrella
Antiplatelet in diabetics: strong but incomplete umbrella Seung-Whan Lee, MD. Heart Institute, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea Global Projections for the Number
More information- Mohammad Sinnokrot. -Ensherah Mokheemer. - Malik Al-Zohlof. 1 P a g e
-1 - Mohammad Sinnokrot -Ensherah Mokheemer - Malik Al-Zohlof 1 P a g e Introduction Two of the most important problems you will face as a doctor are coagulation and bleeding, normally they are in balance,
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationIs there enough evidence for DAPT after endovascular intervention for PAOD?
Is there enough evidence for DAPT after endovascular intervention for PAOD? Prof. I. Baumgartner Head Clinical & Interventional Angiology University Hospital Bern Disclosure Speaker name:...i. Baumgartner...
More informationAntiplatelet agents treatment
Session III Comprehensive management of diabetic patients Antiplatelet agents treatment Chonnam National University Hospital Department of Internal Medicine Dong-Hyeok Cho CONTENTS Introduction Prothrombotic
More informationProf. Jindřich Špinar, MD
Prof. Jindřich Špinar, MD Head of the Internal Cardiology dpt., University Hospital Brno Focuses on clinical cardiology, acute and chronic heart failure, ischemic heart gisease, hypertension Vice head
More informationHow Long Patietns Will Be on Dual Antiplatelet Therapy?
How Long Patietns Will Be on Dual Antiplatelet Therapy? Ron Waksman,, MD, FACC Professor of Medicine (Cardiology) Georgetown University Associate Director, Division of Cardiology, Washington Hospital Center
More informationFigure 13-1: Antiplatelet Action of Aspirin (Modified After Taneja et.al 2004) ASPIRIN RESISTANCE
CHAPTER 13 ASPIRIN Action Aspirin Resistance Aspirin Dose Therapeutic Efficacy - Secondary prevention - Acute coronary syndromes - Primary prevention Limitations and Side Effects Aspirin Aspirin should
More informationColumbia University Medical Center Cardiovascular Research Foundation
STEMI and NSTEMI Pharmacology Confusion: How to Choose and Use Antithrombins (Unfractionated and Low Molecular Heparins, Bivalirudin, Fondaparinux) and Antiplatelet Agents (Aspirin, Clopidogrel and Prasugrel)
More informationUpdate on Antithrombotic Therapy in Acute Coronary Syndrome
Update on Antithrombotic Therapy in Acute Coronary Syndrome Laura Tsang November 13, 2006 Objectives: By the end of this session, you should understand: The role of antithrombotics in ACS Their mechanisms
More informationΠροβληματισμοι στην χρηση αντιαιμοπεταλιακων στα οξέα ισχαιμικά σύνδρομα
Α ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΚΑΙ ΟΜΩΝΥΜΟ ΕΡΓΑΣΤΗΡΙΟ ΙΑΤΡΙΚΗ ΣΧΟΛΗ ΠΑΝΕΠΙΣΤΗΜΙΟΥ ΑΘΗΝΩΝ ΙΠΠΟΚΡΑΤΕΙΟ ΓΕΝΙΚΟ ΝΟΣΟΚΟΜΕΙΟ ΑΘΗΝΩΝ Διευθυντής: Καθηγητής ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Προβληματισμοι στην χρηση αντιαιμοπεταλιακων
More informationLow Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)
Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Caitlin C. Akerman, PharmD PGY2 Cardiology Resident WakeMed Health & Hospitals Raleigh,
More informationWhen and how to combine antiplatelet agents and anticoagulant?
When and how to combine antiplatelet agents and anticoagulant? Christophe Beauloye, MD, PhD Head, Division of Cardiology Cliniques Universitaires Saint-Luc Brussels, Belgium Introduction Anticoagulation
More informationAntiplatelet Therapy: Current Recommendations for Choice of Agent and Concurrent Therapy with Warfarin and Novel Oral Anticoagulants
Antiplatelet Therapy: Current Recommendations for Choice of Agent and Concurrent Therapy with Warfarin and Novel Oral Anticoagulants S. Hinan Ahmed, MD Anti-platelet Therapy: Simple Answer Bare metal stent
More informationAdjunctive Antithrombotic for PCI. SCAI Fellows Course December 8, 2014
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 8, 2014 Theodore A Bass, MD FSCAI Immediate Past-President SCAI Professor of Medicine, University of Florida Medical Director UF Health CV
More informationOptimal antiplatelet and anticoagulant therapy for patients treated in STEMI network
Torino 6 Joint meeting with Mayo Clinic Great Innovation in Cardiology 14-15 Ottobre 2010 Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Diego Ardissino Ischemic vs
More informationConflicts of interest. Very balanced Lilly and team, AZ and BMS
Conflicts of interest Very balanced Lilly and team, AZ and BMS Distal microcirculation receives platelet microparticles Release TxA 2 and plugs microcapillaries Healthy vascular endothelium Prevents (antithrombotic
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationINNOVATIONS 2017: Acute Coronary Syndrome Antiplatelet Therapies in Medical and Invasive Strategies.
INNOVATIONS 2017: Acute Coronary Syndrome Antiplatelet Therapies in Medical and Invasive Strategies. José G. Díez, MD, FACC, FSCAI Associate Professor of Medicine, Baylor College of Medicine Hall Garcia
More informationClopidogrel vs New Antiplatelet Therapy (Prasugrel) Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany
Clopidogrel vs New Antiplatelet Therapy () Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität München, Germany Seoul, April 3, 21 Dual Antiplatelet Therapy for Stenting MACE, % 12 1 8 6 In
More informationתרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון מרכז רפואי רבין
תרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון בי""י מרכז רפואי רבין 1. Why should clopidogrel be replaced? 2. Prasugrel 3. Ticagrelor 4. Conclusions CURE TRIAL ACS pts 20 % reduction
More information'Coronary artery bypass grafting in patients with acute coronary syndromes: perioperative strategies to improve outcome'
'Coronary artery bypass grafting in patients with acute coronary syndromes: perioperative strategies to improve outcome' Miguel Sousa Uva Chair ESC Cardiovascular Surgery WG Hospital da Cruz Vermelha Portuguesa
More informationClopidogrel and ASA after CABG for NSTEMI
Clopidogrel and ASA after CABG for NSTEMI May 17, 2007 Justin Lee Pharmacy Resident University Health Network Objectives At the end of this session, you should be able to: Explain the rationale for antiplatelet
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More informationOral Antiplatelet Therapy in Patients with ACS: A Focus on Prasugrel and Ticagrelor
Oral Antiplatelet Therapy in Patients with ACS: A Focus on Prasugrel and Ticagrelor Nicolas W. Shammas, MS, MD, FACC Coronary and Peripheral Interventionalist Cardiovascular Medicine, PC Research Director,
More informationDisclosure Slide. Controversies in Anticoagulation. Presenter Disclosure Information. Challenges in Anticoagulation
1:15 2:15 PM Challenges in Anticoagulation SPEAKER Nasser Lakkis, MD, FACC, FSCAI Presenter Disclosure Information The following relationships exist related to this presentation: Nasser Lakkis, MD, FACC,
More informationDisclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None
SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to
More informationQUT Digital Repository:
QUT Digital Repository: http://eprints.qut.edu.au/ This is the author s version of this journal article. Published as: Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes.
More informationAdjunctive Antithrombotic for PCI. SCAI Fellows Course December 9, 2013
Adjunctive Antithrombotic for PCI SCAI Fellows Course December 9, 2013 Theodore A Bass, MD FSCAI President SCAI Professor of Medicine, University of Florida Medical Director UF Shands CV Center,Jacksonville
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Optimising Crossover from Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome [CAPITAL OPTI-CROSS] Monique Conway, PharmD, BCPS PGY-2 Cardiology Pharmacy
More informationWhy and How Should We Switch Clopidogrel to Prasugrel?
Case Presentation Why and How Should We Switch Clopidogrel to Prasugrel? Shaul Atar Western Galilee Medical Center Nahariya, ISRAEL Case Description A 67 Y. Old Pt. admitted to IM with anginal CP. DM,
More informationAcute Coronary Syndromes
Overview Acute Coronary Syndromes Rabeea Aboufakher, MD, FACC, FSCAI Section Chief of Cardiology Altru Health System Grand Forks, ND Epidemiology Pathophysiology Clinical features and diagnosis STEMI management
More informationAdults With Diagnosed Diabetes
Adults With Diagnosed Diabetes 1990 No data available Less than 4% 4%-6% Above 6% Mokdad AH, et al. Diabetes Care. 2000;23(9):1278-1283. Adults With Diagnosed Diabetes 2000 4%-6% Above 6% Mokdad AH, et
More informationClopidogrel When For What For How Long. T Benjanuwattra Chiang Mai Heart Cent
Clopidogrel When For What For How Long T Benjanuwattra Chiang Mai Heart Cent Evidence Based Medicine I don t want to put you to sleep But want you to be fully alert Atherothrombosis: A Generalized and
More informationClopidogrel Use in ACS and PCI: Clinical Trial Update
Clopidogrel Use in ACS and PCI: Clinical Trial Update Matthew J. Price MD Director, Cardiac Catheterization Laboratory, Scripps Clinic, La Jolla, CA Assistant Professor, Scripps Translational Science Institute
More informationAn Update on Oral Anti-platelet therapy in patients with non-st Myocardial Infarction. Disclosures
An Update on Oral Anti-platelet therapy in patients with non-st Myocardial Infarction R. Scott Wright, MD, FACC, FESC, FAHA, Professor of Medicine Mayo Clinic Fall Managed Care Forum November 2013 3098590-1
More informationUpdate on Oral Antiplatelet Therapy in Coronary Artery Disease
Update on Oral Antiplatelet Therapy in Coronary Artery Disease Ty J. Gluckman, MD, FACC Providence St. Vincent Heart and Vascular Institute, Portland, Oregon Ciccarone Center for the Prevention of Heart
More informationAntiplatelet Therapy: how, why, when? For Coronary Stenting
Antiplatelet Therapy: how, why, when? For Coronary Stenting Dominick J. Angiolillo, MD, PhD, FACC, FESC, FSCAI Director of Cardiovascular Research Associate Professor of Medicine University of Florida
More informationOUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.
OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To review the use of antiplatelet agents and oral
More informationThe Korean Society of Cardiology COI Disclosure
The Korean Society of Cardiology COI Disclosure Name of First Author: Yongwhi Park The authors have no financial conflicts of interest to disclose concerning the presentation 2017 Annual Spring Scientific
More informationUpdated and Guideline Based Treatment of Patients with STEMI
Updated and Guideline Based Treatment of Patients with STEMI Eli I. Lev, MD Director, Cardiac Catheterization Laboratory Hasharon Hospital, Rabin Medical Center Associate Professor of Cardiology Tel-Aviv
More informationST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department
ST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department decision-making. They have become the cornerstone of many ED protocols for
More informationRobert Storey. Sheffield, United Kingdom
Breakthrough Antiplatelets and Anticoagulants: Focus on brand new drugs Robert Storey Professor of Cardiology, Department of Cardiovascular Science, University of Sheffield and Academic Director and Honorary
More informationTiming of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC
Timing of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC Professor, Medicine/Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Duke Clinical
More information10 Steps to Managing Non-ST Elevation ACS
Pathophysiology of Acute Coronary Syndromes and Potential Pharmacologic Interventions Acute Coronary Syndrome 4. Downstream from thrombus myocardial ischemia/necrosis (Beta-blockers, Nitrates etc) 3. Activation
More informationSession Objectives. Clopidogrel Resistance. Clopidogrel (Plavix )
Session Objectives New Antithrombotics and Real Time Genetic Testing: Their Role in the Vascular Patient Margaret C. Fang, MD, MPH Associate Professor of Medicine Division of Hospital Medicine Medical
More informationΔιάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST How to manage antiplatelet treatment in patients with diabetes in acute coronary syndrome Lars Wallentin Professor of Cardiology, Chief Researcher Cardiovascular Science
More informationDoes COMPASS Change Practice?
Does COMPASS Change Practice? C. Michael Gibson, M.S., M.D. Professor of Medicine, Harvard Medical School Chief, Clinical Research, Beth Israel Deaconess CV Division Chairman, PERFUSE Study Group Founder,
More informationRobert Storey. Sheffield, United Kingdom
Antiplatelet in ACS Moving beyond clopidogrel Robert Storey Professor of Cardiology, Department of Cardiovascular Science, University of Sheffield and Academic Director and Honorary Consultant Cardiologist,
More informationLa Trombosi Arteriosa
La Trombosi Arteriosa Prof. Giovanni Davì Medicina Interna Chieti Platelet activation and thrombosis Harrison 19 edizione Platelets are essential for primary hemostasis and repair of the endothelium They
More informationHeart disease is the leading cause of death
ACS AND ANTIPLATELET MANAGEMENT: UPDATED GUIDELINES AND CURRENT TRIALS Christopher P. Cannon, MD,* ABSTRACT Acute coronary syndrome (ACS) is an important cause of morbidity and mortality in the US population
More informationThe Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease
Interventional Cardiology and Cath Labs The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease Manesh R. Patel MD Chief,
More informationCORONARY AND PERIPHERAL ARTERY ATHEROSCLEROSIS: WHAT CHOICE FOR ANTIPLATELET THERAPY
02_02 03/02/17 14.04 Pagina 9 CORONARY AND PERIPHERAL ARTERY ATHEROSCLEROSIS: WHAT CHOICE FOR ANTIPLATELET THERAPY P. Gresele Department of Medicine, Division of Internal and Cardiovascular Medicine, University
More informationPrasugrel: Son of Clopidogrel or Distant Cousin? Disclosures. Objectives
Prasugrel: Son of Clopidogrel or Distant Cousin? By John J. Bon, Pharm.D., BCPS Lead Clinical Pharmacist, Critical Care Summa Health System Disclosures I have no actual or potential conflict of interest
More informationΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ. Εξατοµικευµένη αντιαιµοπεταλιακή αγωγή. Ποιο είναι το µέλλον?
ΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ ΕΡΕΥΝΗΤΙΚΟ ΚΕΝΤΡΟ ΑΘΗΡΟΘΡΟΜΒΩΣΗΣ Εξατοµικευµένη αντιαιµοπεταλιακή αγωγή. Ποιο είναι το µέλλον? Αλέξανδρος Δ. Τσελέπης, MD, PhD Καθηγητής Βιοχηµείας - Κλινικής Χηµείας Disclosures
More informationPeripheral Artery Disease Role of Exercise, Endovascular and Surgical Options
Peripheral Artery Disease Role of Exercise, Endovascular and Surgical Options Jeffrey W. Olin, D.O., F.A.C.C., F.A.H.A. Professor of Medicine (Cardiology) Director of Vascular Medicine & the Vascular Diagnostic
More informationClinical and Economic Value of Rivaroxaban in Coronary Artery Disease
CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban
More informationReview Article Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes
Review Article Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes Tirtha Patel V *, Jigna Shah S and Patel CN Department of Clinical Pharmacy, Shri Sarvajanik Pharmacy College, Mehsana, Gujarat,
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
More informationAnti-platelet therapies and dual inhibition in practice
Anti-platelet therapies and dual inhibition in practice Therapeutics; Sept. 25 th 2007 Craig Williams, Pharm.D. Associate Professor of Pharmacy Objectives 1. Understand the pharmacology of thienopyridine
More informationSTEMI: Newer Aspects in Pharmacological Treatment
CHAPTER 14 STEMI: Newer Aspects in Pharmacological Treatment P. C. Manoria, Pankaj Manoria Introduction ST elevation myocardial infarction (STEMI) commonly results from disruption of a vulnerable plaque
More informationΚωνσταντίνος Π. Τούτουζας Επ. Καθηγηηής Καρδιολογίας. A Πανεπιζηημιακή Καρδιολογική Κλινική, Ιπποκράηειο Νοζοκομείο
Κωνσταντίνος Π. Τούτουζας Επ. Καθηγηηής Καρδιολογίας A Πανεπιζηημιακή Καρδιολογική Κλινική, Ιπποκράηειο Νοζοκομείο Europe* 2001 2011 Incident MI 291,100 327,700 US 2001 2011 Incident MI 405,100 485,200
More informationNew Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel)
New Antithrombotic and Antiplatelet Drugs in CAD : (Factor Xa inhibitors, Direct Thrombin inhibitors and Prasugrel) Limitations and Advantages of UFH and LMWH Biological limitations of UFH : 1. immune-mediated
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationDual Oral Antiplatelet Therapy for ACS: Improving Standards of Care to Optimize Outcomes
Agenda Welcome and Introduction Pathophysiology of ACS Is Aspirin Enough? Overview of Antiplatelet Agents Clopidogrel Prasugrel Ticagrelor New Guideline Recommendations for Dual Antiplatelet Therapy in
More informationQuinn Capers, IV, MD
Heart Attacks Mended Hearts Presentation, January, 2017 Quinn Capers, IV, MD Associate Professor of Medicine (Cardiovascular Medicine) Director, Transradial Coronary Interventions Division of Cardiovascular
More informationEarly Management of Acute Coronary Syndrome
Early Management of Acute Coronary Syndrome Connie Hess, MD, MHS University of Colorado Division of Cardiology Acute Coronary Syndrome (ACS) A range of conditions associated with sudden imbalance in myocardial
More informationCardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008.
Cardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008. ST Elevation Myocardial Infarction (STEMI)-Acute Coronary Syndrome Guidelines:
More informationThrombosis Research active studies
Thrombosis Research active studies A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients With Coronary Artery Disease Undergoing PCI With CYP2C19 Loss-of-function Genotypes: A Feasibility
More informationUnderstanding and Treating Acute Coronary Syndrome
Page 1 Understanding and Treating Acute Coronary Syndrome Jean M. Nappi, Pharm.D., FCCP, BCPS Professor of Clinical Pharmacy & Outcome Sciences South Carolina College of Pharmacy-MUSC Campus Professor
More informationPlatelet Function Beyond Hemostasis Young-Hoon Jeong, M.D., Ph.D.
Platelet Function Beyond Hemostasis Young-Hoon Jeong, M.D., Ph.D. Director, Clinical Trial Center, Gyeongsang National University Hospital; Associate Professor, Department of Internal Medicine, Gyeongsang
More informationImproving Patient Outcomes: Updated Treatment Strategies in the Management of Acute Coronary Syndrome
Improving Patient Outcomes: Updated Treatment Strategies in the Management of Acute Coronary Syndrome E. Magnus Ohman, MB, FRCPI, FESC, FACC Professor of Cardiovascular Medicine The Kent and Siri Rawson
More informationAntiplatelet Therapy. Briain Mac Neill
Antiplatelet Therapy Briain Mac Neill Galway University Hospital & National University of Ireland Galway Milestones in ACS Management Anti-Thrombin Rx Heparin LMWH Bivalirudin Anti-Platelet Rx Aspirin
More informationOptimal lenght of DAPT in different clinical scenarios
Optimal lenght of DAPT in different clinical scenarios After PCI with DES in the light of recent and ongoing studies Dr Grégoire Rangé / CH Chartres / France DAPT duration depend on the evolution of risk
More informationΑντιαιμοπεταλιακη αγωγη (ποια, πο τε και για πο σο)
Αντιαιμοπεταλιακη αγωγη (ποια, πο τε και για πο σο) Dimitrios Alexopoulos, MD, FESC, FACC Cardiology Department, Patras University Hospital, Patras, Rio, Greece. Patras University Hospital I, Dimitrios
More informationThrombin Receptor Antagonists and Other New Oral Antiplatelets Drugs
Thrombin Receptor Antagonists and Other New Oral Antiplatelets Drugs David J. Moliterno, MD Professor and Chairman Department of Internal Medicine The University of Kentucky Linda and Jack Gill Heart Institute
More informationChanging Course: Anticoagulation in Secondary Prevention of Cardiovascular Disease Events
Changing Course: Anticoagulation in Secondary Prevention of Cardiovascular Disease Events Deepak L. Bhatt, MD, MPH Executive Director Interventional Cardiovascular Programs Brigham and Women s Hospital
More informationTo provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
ACETYL SALICYLIC ACID TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
More information